TNBC Patient
Complete the form to get the full interpretation guide 

The VENTANA PD-L1 (SP142) Assay is a CDx that’s FDA approved to help identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ® (atezolizumab).1,2  You can run this assay on your BenchMark ULTRA system or send it to one of our testing centers.

Form Successfully Submitted!
Thank you for your submission!

We value your privacy.

Find testing sites offering theVENTANA PD-L1 (SP142) Assay
Want to learn more?
PD-L1 educational videos

Learn about the tumor microenvironment, PD-L1 expression on immune and tumor cells and the development process for companion diagnostic tests.

Webcast training

Watch our online microscopy training, “Scoring the VENTANA PD-L1 (SP142) Assay for the TNBC indication,” hosted by Roche Medical and Scientific Affairs Pathologists.

Roche Diagnostics University

Find online training courses for the VENTANA PD-L1 (SP142) Assay. Topics include PD-L1 expression, the tumor microenvironment and information on the other cancer indications.

In addition to TNBC, the VENTANA PD-L1 (SP142) Assay is also indicated for:
Urothelial Carcinoma

The VENTANA PD-L1 (SP142) Assay* is an FDA-approved test predictive for TECENTRIQ® (atezolizumab) in urothelial carcinoma (UC) patients. It is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

*In the US available only on the VENTANA BenchMark ULTRA automated slide staining instrument.

Non-Small Cell Lung Cancer

The VENTANA PD-L1 (SP142) Assay gives you confidence to reliably identify non-small cell lung cancer patients eligible for TECENTRIQ.®